Health-related quality of life and treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial

Richard R. Rubin, Mark Peyrot

    Research output: Contribution to journalArticle

    Abstract

    Objective: This study assessed health-related quality of life (HRQOL) and treatment satisfaction in sensor-augmented pump therapy (SAPT) compared with optimal conventional therapy-multiple daily injection (MDI) therapy with self-monitoring of blood glucose (SMBG)-in adults and children with type 1 diabetes and children's caregivers. Patient acceptance of new therapies is essential to their adoption and effective use. Research Design and Methods: STAR 3, a randomized 12-month clinical trial, compared SAPT with MDI+SMBG in 485 adult and pediatric patients. Within- and between-treatment arm changes in generic HRQOL, diabetes-specific HRQOL (fear of hypoglycemia), and treatment satisfaction were assessed (significance criterion P

    Original languageEnglish (US)
    Pages (from-to)143-151
    Number of pages9
    JournalDiabetes Technology and Therapeutics
    Volume14
    Issue number2
    DOIs
    StatePublished - Feb 2012

    Fingerprint

    Quality of Life
    Blood Glucose Self-Monitoring
    Therapeutics
    Injections
    Type 1 Diabetes Mellitus
    Hypoglycemia
    Caregivers
    Fear
    Research Design
    Clinical Trials
    Pediatrics

    ASJC Scopus subject areas

    • Endocrinology
    • Endocrinology, Diabetes and Metabolism
    • Medical Laboratory Technology

    Cite this

    Health-related quality of life and treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial. / Rubin, Richard R.; Peyrot, Mark.

    In: Diabetes Technology and Therapeutics, Vol. 14, No. 2, 02.2012, p. 143-151.

    Research output: Contribution to journalArticle

    @article{432a77c5096a4ddabfe1dfd642ae065b,
    title = "Health-related quality of life and treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial",
    abstract = "Objective: This study assessed health-related quality of life (HRQOL) and treatment satisfaction in sensor-augmented pump therapy (SAPT) compared with optimal conventional therapy-multiple daily injection (MDI) therapy with self-monitoring of blood glucose (SMBG)-in adults and children with type 1 diabetes and children's caregivers. Patient acceptance of new therapies is essential to their adoption and effective use. Research Design and Methods: STAR 3, a randomized 12-month clinical trial, compared SAPT with MDI+SMBG in 485 adult and pediatric patients. Within- and between-treatment arm changes in generic HRQOL, diabetes-specific HRQOL (fear of hypoglycemia), and treatment satisfaction were assessed (significance criterion P",
    author = "Rubin, {Richard R.} and Mark Peyrot",
    year = "2012",
    month = "2",
    doi = "10.1089/dia.2011.0162",
    language = "English (US)",
    volume = "14",
    pages = "143--151",
    journal = "Diabetes Technology and Therapeutics",
    issn = "1520-9156",
    publisher = "Mary Ann Liebert Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Health-related quality of life and treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial

    AU - Rubin, Richard R.

    AU - Peyrot, Mark

    PY - 2012/2

    Y1 - 2012/2

    N2 - Objective: This study assessed health-related quality of life (HRQOL) and treatment satisfaction in sensor-augmented pump therapy (SAPT) compared with optimal conventional therapy-multiple daily injection (MDI) therapy with self-monitoring of blood glucose (SMBG)-in adults and children with type 1 diabetes and children's caregivers. Patient acceptance of new therapies is essential to their adoption and effective use. Research Design and Methods: STAR 3, a randomized 12-month clinical trial, compared SAPT with MDI+SMBG in 485 adult and pediatric patients. Within- and between-treatment arm changes in generic HRQOL, diabetes-specific HRQOL (fear of hypoglycemia), and treatment satisfaction were assessed (significance criterion P

    AB - Objective: This study assessed health-related quality of life (HRQOL) and treatment satisfaction in sensor-augmented pump therapy (SAPT) compared with optimal conventional therapy-multiple daily injection (MDI) therapy with self-monitoring of blood glucose (SMBG)-in adults and children with type 1 diabetes and children's caregivers. Patient acceptance of new therapies is essential to their adoption and effective use. Research Design and Methods: STAR 3, a randomized 12-month clinical trial, compared SAPT with MDI+SMBG in 485 adult and pediatric patients. Within- and between-treatment arm changes in generic HRQOL, diabetes-specific HRQOL (fear of hypoglycemia), and treatment satisfaction were assessed (significance criterion P

    UR - http://www.scopus.com/inward/record.url?scp=84855840292&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84855840292&partnerID=8YFLogxK

    U2 - 10.1089/dia.2011.0162

    DO - 10.1089/dia.2011.0162

    M3 - Article

    C2 - 22133037

    AN - SCOPUS:84855840292

    VL - 14

    SP - 143

    EP - 151

    JO - Diabetes Technology and Therapeutics

    JF - Diabetes Technology and Therapeutics

    SN - 1520-9156

    IS - 2

    ER -